Infection

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, TFF, Administration, Conference, Patient, IPA, EAP, Mortality, G&A, Lung transplantation, Insurance, AAAM, Microsoft Access, Research and development, Infection, Safety, FDA, Heart, Corporation, Pharmaceutical industry

FORT WORTH, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the fourth quarter and full year 2023.

Key Points: 
  • FORT WORTH, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the fourth quarter and full year 2023.
  • For TFF TAC, the Company presented data showing that eight out of eight patients successfully transitioned from oral Tacrolimus to TFF TAC in the Phase 2 study.
  • TFF TAC continues to demonstrate favorable safety results with no mortality or discontinuations due to adverse events.
  • In the fourth quarter 2023, the Company announced the appointment of three new members of its Board of Directors, including Thomas B.

Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering

Retrieved on: 
Thursday, March 28, 2024
Failure, Madison Avenue, Exercise, Fibromyalgia, Infection, Cocaine, Autoimmunity, Central nervous system, Form, Telephone, Patient, CNS, Research, Sale, NDA, Disease, Cancer, Long, Security (finance), Breakthrough therapy, Nature, Risk, Annual report, Therapy, Series, CD40L, FDA, Sumatriptan, Government, Food

The closing of the offering is expected to take place on or about April 1, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to take place on or about April 1, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds of the offering will be approximately $4.4 million before deducting placement agent fees and other estimated offering expenses payable by the Company.
  • A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.
  • This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No.

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, March 28, 2024
Transcoding, Internal medicine, Temple University Hospital, CFO, Oncology, Patient, RNA, University, Cancer, University of Pittsburgh, Yale School of Medicine, Baylor College of Medicine, Infection, Therapy, Harvard University, Interim, Muscular dystrophy, Yale University, Pharmacia, Pharmaceutical industry

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company’s Chief Medical Officer.

Key Points: 
  • BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company’s Chief Medical Officer.
  • Dr. Vlock is a medical oncologist with over 25 years of industry experience and 15 years in academia, including renowned institutions Yale University, University of Pittsburgh, and Harvard University.
  • While at Pharmacia, Dr. Vlock ran the Celebrex Oncology program involving two pivotal clinical trials and over 3,500 patients.
  • Dr. Vlock initially will serve on a part-time basis through TransCode’s arrangement with BioBridges LLC, a life sciences consulting company.

Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL

Retrieved on: 
Thursday, March 28, 2024
Conditional sentence, Infection, JV, Ocean Biomedical, Risk, Patient, Research, Cancer, HBV, Neoplasm, Therapy, Liver, Safety

The clinical safety of this novel mechanism of action, via checkpoint modification, are supported by the these first data presented at APASL.

Key Points: 
  • The clinical safety of this novel mechanism of action, via checkpoint modification, are supported by the these first data presented at APASL.
  • Treatments for chronic HBV are in high demand and could capture an estimated global market of $6.5+ billion by 2032 .
  • These safety data are another major milestone for our JV partner, Virion, and we look forward to seeing additional safety, and immunological data, at an upcoming meeting.
  • Ocean is pleased to partner with Virion in bringing this technology to patients worldwide and we look forward to helping accelerate this, and other programs, in development.”

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

Retrieved on: 
Thursday, March 28, 2024
Immune system, Vaccine, Infection, Biotechnology, Cancer, COVID-19, Doctor of Philosophy

ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company’s next-generation Covid-19 vaccine candidate, during the upcoming 24th Annual World Vaccine Congress taking place in Washington, DC on April 1-4, 2024.

Key Points: 
  • ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company’s next-generation Covid-19 vaccine candidate, during the upcoming 24th Annual World Vaccine Congress taking place in Washington, DC on April 1-4, 2024.
  • Dr. Newman’s presentation will focus on results delineating the unique immune system driven mechanisms that contribute to the broad efficacy of GeoVax’s next-generation Covid-19 vaccine, GEO-CM04S1.

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, Symantec Endpoint Protection, Prejudice, SPA, Patient, CRL, NDA, G&A, CMC, Disclosure, Insurance, Senior, Woman, Investment, Infection, Therapy, Urinary tract infection, ATM, FDA, ITRM, Food, Pharmaceutical industry

DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Iterum reported positive top-line data in January 2024 and plans to resubmit its NDA early in the second quarter of 2024.
  • In connection with this strategic process, Iterum has engaged a financial advisor to assist management and the board in evaluating strategic alternatives.
  • In addition, during the fourth quarter of 2022, a change in the discount rate impacted the fair value of the Royalty-Linked Notes.
  • Iterum will host a conference call today, Thursday, March 28, 2024 at 8:30 a.m. Eastern Time.

Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development

Retrieved on: 
Thursday, March 28, 2024
Partnership, CRM197, Therapy, GMP, CDMO, Research, Infection, Primrose, Vaccine

Third parties engaged in developing conjugate vaccines will have access to a seamless solution for vaccine conjugation, manufacturing and supply.

Key Points: 
  • Third parties engaged in developing conjugate vaccines will have access to a seamless solution for vaccine conjugation, manufacturing and supply.
  • “We are excited to announce our partnership with Primrose Bio.
  • By combining our expertise with Primrose's cutting-edge technologies, we aim to revolutionize the landscape of conjugate vaccine development, ultimately benefiting millions worldwide."
  • The partnership signifies a strategic alignment aimed at advancing vaccine development and accessibility for researchers and industry clients.

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Retrieved on: 
Wednesday, March 27, 2024
Malignancy, Colitis, Survival, BioNTech, Patient, Lung, City, Standard of care, Quality of life, Fungal infection, Aspergillosis, Nationwide, Clinical trial, Bone marrow, Melanoma, Aspergillus fumigatus, Therapy, Human, Psoriasis, Partnership, World Health Organization, Coccidioides, Safety, Clutch (eggs), University, Kidney, Amphotericin B, Neoplasm, Research, Data monitoring committee, Infection, Skin, Vanderbilt University Medical Center, Hospital, Immunodeficiency, FDA, Critical, Element, Toxicity, IL-17A, Brain, Conference call, Conference, Johns Hopkins, Nephrotoxicity, Docetaxel, Serum, Inflammation, Mouse, Mortality, Fusarium, Bangladesh Technical Education Board, Pharmaceutical industry

BEDMINSTER, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports 2023 financial results and provides a business update.

Key Points: 
  • Aspergillus fumigatus is also included in the FDA qualified designation list of pathogens that pose a serious and life-threatening risk.
  • Revenue for 2023 was $1.1 million, which was generated from the Company’s research collaborations with BioNTech SE and Genentech Inc.
  • Cash, cash equivalents and marketable securities as of December 31, 2023 were $13.8 million compared with $28.8 million as of December 31, 2022.
  • Matinas will host a conference call and webcast today beginning at 4:30 p.m. Eastern time.

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Retrieved on: 
Wednesday, March 27, 2024
Infection, Risk, COVID-19, Patient, Fast Track, Viral, Data monitoring committee, Death, Doctor of Philosophy, Safety, DSMB, Immunodeficiency, Atea, Food, Hospital, Pharmaceutical industry

BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the company has completed enrollment of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, or placebo for the treatment of COVID-19. Over 2,200 patients were randomized into the supportive care monotherapy cohort and less than 80 patients were randomized into the combination cohort. The primary endpoint of the trial is all-cause hospitalization or death through Day 29 post-treatment in the bemnifosbuvir supportive care monotherapy cohort of high-risk patients. Secondary endpoints include other measurements of patient outcomes through Day 60 post-treatment.

Key Points: 
  • Over 2,200 patients were randomized into the supportive care monotherapy cohort and less than 80 patients were randomized into the combination cohort.
  • The primary endpoint of the trial is all-cause hospitalization or death through Day 29 post-treatment in the bemnifosbuvir supportive care monotherapy cohort of high-risk patients.
  • Secondary endpoints include other measurements of patient outcomes through Day 60 post-treatment.
  • “COVID-19 continues to be a threat, leaving the most vulnerable at risk for severe outcomes from infection.

Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium

Retrieved on: 
Wednesday, March 27, 2024
Opacity (optics), Risk, Patient, RBS, University, PDAT, Bascom Palmer Eye Institute, Rose bengal, Eye, Infection, Keratitis, Safety, Paratriathlon, Ophthalmology, OBC, Pharmaceutical industry

Provectus would contribute the license to the new entity and have an exclusive RBS supply arrangement with it.

Key Points: 
  • Provectus would contribute the license to the new entity and have an exclusive RBS supply arrangement with it.
  • Rose bengal PDAT emerged under the leadership of Jean-Marie Parel, IngETS-G, Ph.D., FARVO, Director of the Ophthalmic Biophysics Center (“OBC”) at Bascom Palmer Eye Institute (“BPEI”) at the University of Miami Miller School of Medicine.
  • The OBC team and Dr. Parel have spent many years advancing their PDAT technology using rose bengal against different types of treatment-naïve and -resistant keratitis.
  • Dr. Parel said, “Rose bengal PDAT is the result of a lot of hard work by cross-disciplinary contributors at the University of Miami.